Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people with HIV.

José Damas Aline Munting Jacques FellayDavid HaerryCatia Marzolini Philip E TarrAna SteffenDominique L BraunMarcel StoeckleEnos BernasconiOlivier Nawej TshikungChristoph A FuxKatharine E A Darling Charles Béguelin Gilles Wandeler Matthias Cavassini Bernard Surialnull null

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)

Replacing TAF with TDF in PWH led to a decrease in body weight and an improved lipid profile within one year. Weight changes were not observed among individuals who switched to DTG/3TC or long-acting CAB/RPV.

Keyphrases

body weight
antiretroviral therapy
hiv infected
hiv positive
human immunodeficiency virus
hiv aids
hiv infected patients
body composition
physical activity
body mass index
weight loss
hepatitis c virus
men who have sex with men
hiv testing